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Quantitative analysis of protease 
recognition by inhibitors in plasma 
using microscale thermophoresis
T. Dau1,*, E. V. Edeleva2,3,*, S. A. I. Seidel2, R. A. Stockley4, D. Braun2 & D. E. Jenne1,5
High abundance proteins like protease inhibitors of plasma display a multitude of interactions 
in natural environments. Quantitative analysis of such interactions in vivo is essential to study 
diseases, but have not been forthcoming, as most methods cannot be directly applied in a complex 
biological environment. Here, we report a quantitative microscale thermophoresis assay capable of 
deciphering functional deviations from in vitro inhibition data by combining concentration and affinity 
measurements. We obtained stable measurement signals for the substrate-like interaction of the 
disease relevant inhibitor α-1-antitrypsin (AAT) Z-variant with catalytically inactive elastase. The signal 
differentiates between healthy and sick AAT-deficient individuals suggesting that affinity between AAT 
and elastase is strongly modulated by so-far overlooked additional binding partners from the plasma.
One of the fundamental regulatory mechanisms in cell biology is the finely tuned interaction between enzymes 
and their substrates1. Binding between an enzyme and a substrate is most likely strongly influenced by the com-
position of the biological buffer system, for example by various plasma components2. However, functional assess-
ment of protein-protein interactions in native environments has been a major challenge to date3,4.
Immunoassays and surface plasmon resonance are the current standard approaches to quantitate concentra-
tions in plasma and to determine affinities of potential known targets5,6. However, both methods require surface 
immobilization of an antigen or an antibody, potentially imposing steric hindrance and molecular activity prob-
lems. Immobilization-free approaches based on fluorescence resonance energy transfer (FRET) require availabil-
ity and labeling of both interacting partners7,8. Therefore, FRET-based methods cannot determine the affinity of 
a person-specific endogenous protein to a known target of interest in a plasma sample.
Microscale thermophoresis (MST) is a recently established immobilization-free affinity measurement tech-
nique that has been applied to characterize ligand-binder interactions and affinity constants ranging from pM to 
mM under challenging conditions9–11. MST employs the physical phenomenon of thermophoresis – movement 
of molecules in a temperature gradient. Biomolecules tend to move against the temperature gradient causing the 
depletion of a biomolecule in the heated spot. In the MST binding measurement, the depletion of the fluores-
cently labeled binder changes upon ligand binding. Measurement of depletion at increasing ligand concentrations 
results in a binding curve, which can be used to derive the affinity.
In our previous work using an MST-based approach, we showed how the affinity as well as the concentration 
of the ligand can potentially be determined in complex matrices such as blood serum12. The first limitation of this 
method is the sensitivity as only an additionally spiked but not initially present ligand could be detected in serum. 
Secondly, low affinity interactions remain a challenge, as they often require unrealizable high concentrations of 
the unlabeled binder to establish a complete binding curve.
An important clinically relevant example of protein interactions in plasma is the inhibition of the enzyme neu-
trophil elastase (NE) by α -1-antitrypsin (AAT). Low plasma levels of AAT predispose to emphysema and chronic 
obstructive pulmonary disease13,14. Decreased AAT levels are often caused by the relatively common Z-mutation 
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Figure 1. Dependency of the amplitude on the AAT concentration and the dissociation constant of NE-AAT  
binding. (a) Describes the theoretical background of the method. At each data point, the inhibitor I1 (here: 
AAT) competes with I2 (here: elafin) for the enzyme E (here: labeled inactive NE). The affinity between E and 
I2 is much higher than the affinity between E and I1. (b) To a constant amount of plasma (7.5%) containing 
I1 and a constant amount of E (500 pM) increasing concentrations of I2 were added and the thermophoretic 
depletion measured. Titration curves with theoretical fits are given for three individuals (patients 1, 8 and 10) 
as examples in (b). All individuals were homozygous for the Z-variant AAT. Each depletion value is given as 
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(Glu342Lys)15 which accounts for 95% of patients with clinically relevant manifestations. Although all individu-
als with the Z-mutation have reduced AAT levels, development of lung emphysema is highly variable among ZZ 
carriers and some are minimally affected13,14,16.
The interaction between NE and AAT has been well studied in vitro using the two purified interacting proteins 
in standard buffers17. AAT inhibits NE irreversibly in a two-step reaction18. The first and rate-determining step 
is the formation of a reversible encounter complex between NE and AAT, where AAT mimics a substrate19,20. 
Previous approaches focused only on the concentration of AAT5,13,15,16, although kinetically efficient formation of 
this encounter complex also depends on the dissociation constant between NE and AAT19,20.
In this work, we developed a novel assay that overcomes the limitations of the previous approaches and 
allowed us to characterize the formation of the NE-AAT encounter complex at the given AAT level of a blood 
plasma sample under constant equilibrium conditions.
Results
Method development: combining concentration and affinity. In our assay, a low affinity inhibitor 
I1 (here: AAT) competes with a high affinity inhibitor I2 (here: elafin) for a catalytically inactive labeled enzyme 
E (here: NE) (Fig. 1a). Inactivation of E was important to prevent the removal of I1 from the equilibrium by the 
irreversible formation of a covalent complex, thereby allowing us to analyze the encounter reaction in the plasma 
environment.
The labeled E at a fixed final concentration of 500 pM was mixed with 12-fold diluted plasma containing the 
analyte I1. To obtain binding curves, increasing amounts of I2 were then added and thermophoretic depletion of 
free E and E bound to I1 (EI1) or I2 (EI2) was measured for each concentration of I2 (Fig. 1a,b). We observed that 
the depletion in the low end range of I2 concentrations varied between plasma samples while the depletion in the 
high end range of I2 concentrations did not change (Fig. 1b).
To compare the binding curves, we introduced a normalized parameter, the thermophoretic amplitude, 
by calculating the difference between the depletion signals in these two I2 concentration ranges (Fig. 1b, 
Supplementary Information 1). We observed that the thermophoretic amplitude varied between plasma samples. 
We hypothesized that I1 concentrations and, more importantly, I1 affinities to E are not necessarily constant in the 
person-specific proteomic environment of plasma samples (Fig. 1b).
To characterize the system at different affinities between I1 and E (Fig. 1c) and different I1 concentrations 
(Fig. 1d), we described it with the mass action law equations and simulated the corresponding binding curves. 
The simulation results indicate that the thermophoretic amplitude increases with an increasing KD(EI1) (Fig. 1c 
small insertion graph) and decreases with increasing I1 concentrations (Fig. 1d small insertion graph). Hence, 
the thermophoretic amplitude reports on both I1 concentration and KD(EI1) (a detailed mathematical analysis is 
provided in the Supplementary Information 2).
Thermophoretic amplitude is better correlated with disease status. To evaluate whether the 
thermophoretic amplitude that includes affinity variations represents a better lung function parameter than AAT 
concentration alone, we determined both parameters in plasma samples of individuals homozygous for the AAT 
Z-variant. We then compared these to FEV1 (the forced expiratory volume in one second) expressed as the per-
centage (%) predicted for age, sex, height, and race, which is widely used to assess the level of airway obstruction 
and bronchoconstriction in AAT-deficient individuals16,21.
In order to avoid measuring the concentration of inactive AAT, we titrated the concentration of functional 
plasma AAT with purified and active site-titrated NE. We observed a significantly lower thermophoretic ampli-
tude (P = 0.0008) with plasma samples from individuals showing a high FEV1 (≥ 80%) than from those with 
low FEV1 (< 80%) (Fig. 2a), while the concentration of functional AAT did not differ between the two groups 
(P = 0.6368). Hence, inclusion of affinity with our method resulted in a much better relationship to disease status 
and severity. To explain the discrepancy between the two quantification methods, we reasoned that KD(EI1) of the 
Z-variant in fact varied in the plasma samples.
Z-variant AAT is sensitive to plasma environments. To investigate whether affinity is indeed sensi-
tive to a given plasma environment, we determined the KD(EI1) of the AAT Z-variant in the two AAT-deficient 
plasma pools from persons with high (≥ 80%) and low FEV1 (≤ 50%) values (Fig. 3). To facilitate the recombi-
nant production of the aggregation-prone Z-variant, we combined three stabilizing mutations derived from the 
work of Lee et al.22 – Met374Ile, Ser381Ala, Lys387Arg – and introduced them into the Z-variant. As a control, 
we expressed AAT without the Z-mutation but containing the same stabilizing mutations. The affinity of the 
Z-variant to NE was more than two times better in the plasma pool from individuals with high FEV1 (≥ 80%) 
(KD(EI1) = 500 ± 100 nM) than from individuals with low FEV1 (≤ 50%) (KD(EI1) = 1300 ± 250 nM), confirm-
ing the plasma-dependent change in the affinity between NE and Z-variant AAT as observed with our newly 
developed assay. Additionally, we found that the Z-mutation improves the encounter reaction of AAT with 
mean ± S.D. from three technical replicates. The amplitude is defined as the difference of minimal depletion 
signals in the low end range (dark grey box with arrow) and maximal depletion signals in the high end range 
of I2 concentrations (light grey box with arrow). The thermophoretic depletion of free E is smaller than that 
of E bound to I1 or I2, and depletion at each I2 concentration indicates the proportion of bound E. (c,d) Are 
simulations according to the mass action laws. (c) Shows that the theoretical amplitude (simulated as the 
amount of bound E) increases when the dissociation constant between E and I1 increases. (d) On the other 
hand, the theoretical amplitude decreases with the increasing concentrations of I1.
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NE (Supplementary Fig. 1a) and Z-variant AAT is more susceptible to plasma components than control AAT 
(Supplementary Fig. 1b).
Discussion
By incorporating a high affinity ligand in thermophoretic measurements, we expanded the spectrum of appli-
cations towards the low affinity range where e.g. enzyme-substrate interactions take place. This new approach 
allowed us to detect unexpected plasma-dependent interferences with AAT, suggesting that the functional capac-
ity of the Z-variant AAT is determined by the heterogeneity of other plasma components, which modulate the 
affinity of AAT towards target enzymes. For example, it was reported23,24 and has been confirmed by our group 
(unpublished) that lipoproteins bind to wildtype AAT, thereby influencing its inhibition of NE and thus could 
also affect the reactivity of the Z-variant in the plasma environment.
The analysis of the interaction between AAT and NE in plasma with our assay provides a possible expla-
nation of the variability in disease development in ZZ carriers. Normally, the reduced AAT plasma levels in 
Figure 2. Thermophoretic amplitude, but not plasma concentration of AAT is associated with disease 
severity. (a) ZZ-carriers (n = 26) were divided into two groups with high FEV1 (≥ 80%, n = 8) and low FEV1 
(< 80%, n = 18), which is a clinical parameter of airway obstruction. The thermophoretic amplitude was 
significantly lower (P = 0.0008) in samples with high FEV1 (***P < 0.001; ns not significant). The amplitude 
is given as a mean value determined from at least two independent experiments. (b) The concentration of 
functional AAT was not significantly different (P = 0.6368) between the groups with high FEV1 (≥ 80%) and low 
FEV1 (< 80%). The AAT concentration was measured twice by elastase titration in duplicates, and is given as a 
mean value here.
Figure 3. Plasma-dependent change in affinity of NE-AAT binding. We compared the affinity between AAT 
and NE in two pools of plasma from individuals with high FEV1 (≥ 80%, n = 8) and low FEV1 (≤ 50%,  
n = 12). The affinity between Z-variant of AAT and NE was higher in plasma with high FEV1 (≥ 80%) 
(KD(EI1) = 500 ± 100 nM) compared to low FEV1 (≤ 50%) (KD(EI1) = 1300 ± 250 nM). Presented binding 
curves represent example measurements where each measurement point (mean ± S.D.) was derived from three 
technical replicates. Fitted binding curves and KD(EI1) values (mean ± S.D.) were derived from global fitting 
of four measurements (three independent protein expressions). The measurements were performed in 7.5% 
plasma and with 5 nM of labeled NE.
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ZZ carriers are compensated by the enhanced affinity of Z-variant AAT to NE. However, the enhanced affinity 
between Z-variant AAT and NE can be disrupted by plasma factors, especially in individuals who have higher 
concentrations of interfering plasma components.
Our work underscores the importance of the endogenous personally unique and distinct environment where 
substrates interact with enzymes with relatively low affinity in a complex web of other proteins and lipid com-
ponents. Such personalized variations and effects have often been overlooked. Our approach may open a way to 
study how other components from the native environments interfere with biochemical reactions.
Methods
Production of recombinant proteins. As the natural Z-variant is on a M1(Ala213) background, we 
amplified a cDNA fragment encoding the M1(Ala213) variant using the primer DJ3689 (5′ -GACTTCCACG 
TGGACCAGGCGACCACCGTGAA-3′ ) and DJ3613 (5′ -GATGACCGGTTTTTTGGGTGGGATTCAC 
CACTT-3′ ) (cursive: restriction site; bold: mutation) and cloned it into the Pml I and Age I site of the previously 
described M1(Val213) AAT construct in pTT5 plasmid (Perera et al.25. To introduce the Z-mutation (Glu342Lys), 
a PCR fragment was generated with the primers DJ3557 (5′ -CCACGATATCATCACCAAGTTCCT-3′ ) and 
DJ3558 (5′ -GTATGGCCTCGAGGAACATGGCCCCAGCAGCTTCAGTCCCTTTCTTGTCGATGGT-3′ ) and 
inserted into the M1(Ala213) AAT pTT5 plasmid between the Eco RV and Abs I sites. The three stabilizing muta-
tions (M374I, S381A, K387R) were introduced by PCR using the following forward and backward primers DJ 3646 
(5′ - CACGATATCATCACCAAGTTCCTGGAAAATGAAGACAGAAGGTCTGCCGACTTACATTTACC-3′ ) 
and DJ3696 (5′ -ATGACCGGTTTTTTGGGTGGGATTCACCACTCTTCCCATGAAGAGGGGAGC CTTGGT 
ATTTTGTTCAATAATTAAG-3′ ) respectively. The product was inserted into the Eco RV and Age I sites.
To produce a catalytically inactive variant of NE, we mutated the Ser195 to Ala195 by inserting an oligo duplex 
(DJ3532 (5 ′  -GTGAACGTATGCACTCTGGTGCCACGTCGGCAGGCAGGCATCTGCT TCGG 
GGACGCT-3′ ) and DJ3533 (5′ -CGTCCCCGAAGCAGATGCCTGCCTGCCGACGTGGCACCAGAGTG 
CATACGTTCACAC-3′ )) into the Alf I site of the previously described wildtype mouse NE construct in pTT5 
(Dau et al.26. To enable site-specific labeling of NE, we added a C-terminal short peptide with a cysteine flanked by 
three aspartate residues on each side by the insertion of an oligoduplex (DJ3632 (5′ - CTAGCGACGACGATTG 
CGACGATG ATC-3′ ) and DJ3633 (5′ - CTAGGATCATCGTCGCAATCGTCGTCG-3′ )) into the Avr II site.
All proteins were expressed in HEK293 EBNA cells (Yves Durocher, National Research Council Canada, 
Montreal, Canada) in FreeStyleTM 293 expression medium (Thermo Fisher Scientific Inc.), 1% Pluronic and 
G418 (25 μ g ml−1) at 37 °C and 8% CO2.
Labelling of NE. First, we added 1 mM DTT to the recombinant NE in storage buffer (20 mM Na2HPO4, 
300 mM NaCl pH 7.4) and incubated it for two hours at room temperature to reduce all cysteine-tags. Then 
we removed DTT by precipitating NE with 75% ammonium sulfate. This reduction and precipitation step was 
repeated once. NE was dissolved in storage buffer and incubated at room temperature for one hour after adding a 
5-fold molar excess of dye (Alexa Fluor® 647 NHS Ester, ThermoFisher Scientific). To remove the excess dye, the 
solution was added to PD MiniTrap G-10 column (GE Healthcare) according to the manufacturers instruction.
Determination of AAT concentration in blood plasma. After titrating trypsin (Sigma-Aldrich, 
St. Louis) with 4-nitrophenyl 4-guanidinobenzoate (Sigma-Aldrich, St Louis, USA) in veronal buffer, AAT 
(Athens Research & Technology, Athens, GA, USA) was titrated against trypsin. A dilution series of AAT 
was incubated with a constant amount of trypsin at 37 °C for 1 hour. The residual activity was measured using 
Boc-Gln-GLy-Arg-AMC. Thereafter, a dilution series of the titrated AAT was incubated with a constant volume 
of active human NE (Elastin Products Company, Inc., Owensville) at 37 °C for 1 hour. The remaining activity was 
measured with MCA-GEAIPTSIPPEVK(Dnp)-rr (EMC microcollections, Tübingen, Germany). All reactions 
were performed in 150 mM NaCl, 50 mM Tris, 0.01% Triton-X-100, pH 7.4.
Active site titrated neutrophil elastase was added to a dilution series of plasma and incubated at 37 °C for 
1 hour. The plasma was diluted in 150 mM NaCl, 50 mM Tris, 0.01% Triton-X-100, pH 7.4. The residual activity 
was measured using MCA-GEAIPTSIPPEVK(Dnp)-rr (EMC microcollections, Tübingen, Germany).
Determination of the concentration of recombinant AAT. A dilution series of AAT-variants was 
incubated with 1.6 nM active site titrated human NE at 37 °C for 1 hour. The residual activity was measured using 
MCA-GEAIPTSIPPEVK(Dnp)-rr (EMC microcollections, Tübingen, Germany).
Statistical analysis. Results are given as median values. A Mann-Whitney test without assuming Gaussian 
distribution was applied to all studies (***P < 0.001). Statistical analyses were done with GraphPad Prism 6 soft-
ware (GraphPad Software).
Development of the Binding Model for Simulations. Mass action law equations with two dissociation 
constants were used to describe the dependency of free NE on the concentration of AAT and on the affinity of 
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K I D1  – dissociation constant of NE – AAT interaction,
K I D2  – dissociation constant of NE – elafin interaction,
[E], [I1], [I2] – total concentrations of NE, AAT, and elafin in the reaction, respectively,
[EI1] – concentration of NE-AAT complex in the reaction,
[EI2] – concentration of NE-elafin complex in the reaction,
= +x EI EI
E
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1 2  – fraction of occupied NE,
Equation (2) was solved for [E], which was then applied to equation (1) to yield a cubic equation for x. The cubic 
equation was solved numerically in Igor Pro 5.03 and the smallest real root of the equation was then used to plot 
the fraction of bound NE x against different elafin concentrations I2 to simulate binding curves.
Determination of the thermophoretic amplitude. Human recombinant elafin (Sigma-Aldrich) was 
serially diluted (1:1) over five orders of magnitude in PBS. Separately, plasma was diluted (final concentration: 
7.5%) with storage buffer substituted with 0.02% Tween 20 and anti-photobleaching enzyme and substrate com-
ponents (Monolith Anti Photobleach Kit, NanoTemper Technologies) were added. This plasma solution was 
mixed 1:1 with PBS for background measurements. After adding fluorescently labeled NE (final concentration: 
500 pM) to the plasma solution, we mixed this 1:1 with each concentration of the serial elafin dilution. The sam-
ples were loaded into the Monolith™ NT.115 premium coated capillaries (NanoTemper Technologies), and incu-
bated at 22 °C for 2 hours. The samples were measured in the instrument (Monolith NT.115Pico, NanoTemper 
Technologies) at 22 °C using 60% light-emitting diode and 40% infrared laser (IR) powers with IR laser on/off 
times of 25/5 seconds. Each dilution point was measured in triplicates. For each plasma sample, the whole proce-
dure was repeated three times to yield independent triplicates.
In Matlab R2014a (8.3.0.532), the time trace of the background signal was subtracted from the time traces 
of the sample signals. Then, the fluorescence after the temperature jump and equilibrated thermophoresis was 
normalized to the fluorescence before the IR laser heating yielding fluorescence depletion values. Fluorescence 
depletion values of three technical replicates (mean ± S.D.) were plotted in per mille units (‰) on a linear y-axis 
against the concentration of the serially diluted elafin on the log10 x-axis resulting in binding curves. The binding 
curves were shifted so that the depletion value at the baseline, where elafin concentration is saturating, was the 
same. In Igor Pro 5.03, a weighted fit to the quadratic solution of the mass action law was performed to yield the 
amplitude A of each curve:
=
+ + − + + −
+f x A











KD – dissociation constant of NE – elafin interaction,
[E] – total concentration of NE,
x – total concentration of elafin,
A – the amplitude of the curve,
t – y-offset of the curve,
with A, t, and KD as free fit parameters.
Determination of dissociation constant between AAT and NE. Freshly purified AAT was serially 
diluted (1:1) over five orders of magnitude in storage buffer. Separately, plasma was diluted in storage buffer 
substituted with 0.2% Tween 20 (final concentration: 7.5%) and anti-bleaching reagents were added. This plasma 
solution was mixed 1:1 with storage buffer for background measurements. Fluorescently labeled NE (final con-
centration: 5 nM) was added to the plasma solution and mixed 1:1 with the serial dilution of AAT. The samples 
were incubated at 22 °C for 2 hours and measured at 22 °C in the instrument using 40% light-emitting diode and 
40% infrared laser (IR) powers with IR laser on/off times of 20/5 seconds.
Binding curves were obtained as described for the determination of the thermophoretic amplitude. They were 
then additionally normalized to 0 at the lowest AAT concentration and to 1 at the highest AAT concentration. 
This corresponds to the proportion of bound NE at each titration point. The global fit of at least three replicates 
to the quadratic solution of the mass action law was performed to yield the dissociation constant of each curve.
Plasma samples. FEV1 was determined post bronchodilator treatment and according to the British Thoracic 
Society/Association of Respiratory Technicians and Physiologists (BTS/ARTP) guidelines as described previ-
ously21. All subjects provided written informed consent, and ethical approval was obtained for all aspects of this 
study (South Birmingham Research Ethics Committee LREC 3359).
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